ATE332294T1 - Dihydro-1,3,5-triazin-diamin-derivate und ihre therapeutische verwendung - Google Patents

Dihydro-1,3,5-triazin-diamin-derivate und ihre therapeutische verwendung

Info

Publication number
ATE332294T1
ATE332294T1 AT01907700T AT01907700T ATE332294T1 AT E332294 T1 ATE332294 T1 AT E332294T1 AT 01907700 T AT01907700 T AT 01907700T AT 01907700 T AT01907700 T AT 01907700T AT E332294 T1 ATE332294 T1 AT E332294T1
Authority
AT
Austria
Prior art keywords
triazine
dihydro
therapeutic use
diamine derivatives
diamine
Prior art date
Application number
AT01907700T
Other languages
English (en)
Inventor
Gerard Moinet
Daniel Cravo
Liliane Doare
Micheline Kergoat
Didier Mesangeau
Original Assignee
Merck Sante Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8846333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE332294(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sante Sas filed Critical Merck Sante Sas
Application granted granted Critical
Publication of ATE332294T1 publication Critical patent/ATE332294T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/10—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/72—Heterocyclic compounds containing 1,3,5-triazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01907700T 2000-01-26 2001-01-25 Dihydro-1,3,5-triazin-diamin-derivate und ihre therapeutische verwendung ATE332294T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0000996A FR2804113B1 (fr) 2000-01-26 2000-01-26 Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique

Publications (1)

Publication Number Publication Date
ATE332294T1 true ATE332294T1 (de) 2006-07-15

Family

ID=8846333

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01907700T ATE332294T1 (de) 2000-01-26 2001-01-25 Dihydro-1,3,5-triazin-diamin-derivate und ihre therapeutische verwendung

Country Status (36)

Country Link
US (4) US7034021B2 (de)
EP (1) EP1250328B2 (de)
JP (1) JP4926357B2 (de)
KR (1) KR100722438B1 (de)
CN (1) CN1195743C (de)
AP (1) AP2002002578A0 (de)
AR (1) AR027293A1 (de)
AT (1) ATE332294T1 (de)
AU (1) AU782307B2 (de)
BG (1) BG106933A (de)
BR (1) BRPI0107815B8 (de)
CA (1) CA2397636C (de)
CY (1) CY1105344T1 (de)
CZ (1) CZ303445B6 (de)
DE (1) DE60121294T3 (de)
DK (1) DK1250328T4 (de)
EA (1) EA005378B1 (de)
EE (1) EE05003B1 (de)
ES (1) ES2267715T5 (de)
FR (1) FR2804113B1 (de)
HR (1) HRP20020625A2 (de)
HU (1) HU230790B1 (de)
IL (1) IL150530A0 (de)
IS (1) IS6467A (de)
MA (1) MA25650A1 (de)
MX (1) MXPA02007232A (de)
NO (1) NO20023532L (de)
OA (1) OA12165A (de)
PL (1) PL205345B1 (de)
PT (1) PT1250328E (de)
SI (1) SI1250328T2 (de)
SK (1) SK287647B6 (de)
TN (1) TNSN01012A1 (de)
WO (1) WO2001055122A1 (de)
YU (1) YU55602A (de)
ZA (1) ZA200205314B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
US7622469B2 (en) 2002-12-17 2009-11-24 Hamari Chemicals, Ltd. 2,4-diamino-1,3,5-triazine derivatives
FR2853650B1 (fr) * 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
ATE489370T1 (de) * 2005-06-14 2010-12-15 Schering Corp Herstellung und verwendung von verbindungen als aspartylproteasehemmer
FR2896160B1 (fr) * 2006-01-13 2008-04-25 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agonistes du ppar alpha.
FR2896157B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
FR2896158B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'inhibiteurs de la hmg-coa reductase.
FR2896159B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
FR2896161B1 (fr) * 2006-01-13 2008-04-04 Merck Sante Soc Par Actions Si Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique.
DE102007054416A1 (de) * 2007-11-13 2009-05-14 Studiengesellschaft Kohle Mbh Verfahren zur Herstellung von 3,6-Dihydro-1,3,5- Triazin-Derivaten für die Behandlungen von Erkrankungen, die mit dem Insulinresistenz-Syndrom assoziiert sind
DE102008007314A1 (de) 2008-02-02 2009-08-06 Merck Patent Gmbh Verfahren zur Herstellung von 3,6-Dihydro-1,3,5-triazinderivaten
ATE536347T1 (de) 2008-05-20 2011-12-15 Merck Sharp & Dohme Effiziente herstellung heterologer proteine unter verwendung von mannosyltransferaseinhibitoren
US20110124860A1 (en) * 2008-05-23 2011-05-26 Aubourg Stephanie Process for the synthesis of 3,6-dihydro-1,3,5-triazine derivatives
WO2010024225A1 (ja) * 2008-08-25 2010-03-04 浜理薬品工業株式会社 新規ジヒドロトリアジン誘導体
ES2530223T3 (es) 2008-12-12 2015-02-27 Poxel S.A.S. Combinación de insulina con derivados de triazina y su uso para tratar la diabetes
JP5485292B2 (ja) * 2008-12-12 2014-05-07 ポクセル・エスアーエス Ａｍｐｋ活性に関連する疾患を処置するためのテトラヒドロトリアジン化合物
WO2010103040A1 (en) 2009-03-10 2010-09-16 INSERM (Institut National de la Santé et de la Recherche Médicale) 5'-adenosine monophosphate-activated protein kinase (ampk) activators for treating pulmonary hypertension
US8742102B2 (en) 2009-03-26 2014-06-03 Poxel Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization
FR2948028B1 (fr) 2009-07-17 2011-12-02 Merck Sante Sas Association d'un inhibiteur de l'echangeur sodium-proton et d'un derive amine de dihydro-1,3,5-triazine
FR2948027A1 (fr) * 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
FR2948026B1 (fr) 2009-07-17 2011-12-02 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine
WO2011154496A1 (en) 2010-06-09 2011-12-15 Poxel Treatment of type 1 diabetes
TWI436768B (zh) 2010-06-09 2014-05-11 Poxel 第２型糖尿病之治療
EP2646422B1 (de) 2010-12-01 2015-07-08 Poxel Trennung von triazinderivatenantiomeren durch weinsäure
RU2658819C2 (ru) * 2016-05-26 2018-06-25 федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный технический университет" Применение гетероциклических гидразонов в качестве средств, обладающих антигликирующей активностью
FR3068601B1 (fr) * 2017-07-05 2021-02-19 Eric Joseph Marie Fulgence Janin Utilisation de l'imeglimine pour la prevention et/ou le traitement du carcinome hepatocellulaire
EP3691650A1 (de) 2017-10-02 2020-08-12 Poxel Verfahren zur behandlung von herzversagen mit bewahrter ejektionsfraktion
MY203360A (en) * 2018-06-06 2024-06-26 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
CA3103324A1 (en) 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
WO2022152138A1 (zh) * 2021-01-15 2022-07-21 中国医药研究开发中心有限公司 稠和杂环类化合物及其制备方法和医药用途
CN118955413A (zh) * 2024-07-25 2024-11-15 宁夏恒康科技有限公司 一种盐酸伊美格列明的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3287366A (en) * 1963-12-24 1966-11-22 American Cyanamid Co Novel 1, 2-dihydro-s-triazines
US3286366A (en) * 1964-10-26 1966-11-22 Seligman Monroe Apparatus for freeze drying products in small containers
JPS4856692A (de) * 1971-11-19 1973-08-09
JPS4864088A (de) * 1971-12-13 1973-09-05
JPS5414986A (en) * 1977-07-01 1979-02-03 Taiho Pharmaceutical Co Ltd Production of dihydrooss triazine derivative
US4246408A (en) * 1979-03-08 1981-01-20 Icn Pharmaceuticals Imidazo[1,2-a]-s-triazine
GR74944B (de) * 1980-07-02 1984-07-12 Merck & Co Inc
US4277602A (en) * 1980-07-02 1981-07-07 Merck & Co., Inc. 3-Amino-5-substituted-6-halo-N-(3,4-dihydro-6-substituted-1,3,5-truazin-2-yl)2-pyrazinecarboxamides
US4576945A (en) * 1982-10-26 1986-03-18 Sanders Mark E Hexaalkylmelamine-amino-oxy compounds
JPS6141915A (ja) 1984-08-03 1986-02-28 Omron Tateisi Electronics Co 測距装置
DD257010A1 (de) * 1987-01-13 1988-06-01 Berlin Chemie Veb Ergotrope mittel
DE3801113A1 (de) * 1987-07-23 1989-02-02 Bayer Ag Substituierte triazine
IT1244870B (it) * 1990-09-11 1994-09-12 Ministero Dall Uni E Della Ric Composti ammelinici
DE19641692A1 (de) * 1996-10-10 1998-04-23 Bayer Ag Substituierte 2,4-Diamino-1,3,5-triazine
CN1290264A (zh) * 1997-12-12 2001-04-04 艾博特公司 三嗪类血管生成抑制剂
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique

Also Published As

Publication number Publication date
EP1250328B1 (de) 2006-07-05
AU782307B2 (en) 2005-07-21
EE05003B1 (et) 2008-04-15
CA2397636C (fr) 2010-04-06
JP4926357B2 (ja) 2012-05-09
HUP0204087A2 (hu) 2003-04-28
HRP20020625A2 (en) 2003-10-31
PL357191A1 (en) 2004-07-26
NO20023532D0 (no) 2002-07-24
FR2804113B1 (fr) 2004-06-18
HU230790B1 (en) 2018-05-02
EP1250328A1 (de) 2002-10-23
CZ303445B6 (cs) 2012-09-19
WO2001055122A1 (fr) 2001-08-02
OA12165A (fr) 2006-05-08
SI1250328T1 (sl) 2006-10-31
NO20023532L (no) 2002-09-25
CZ20022462A3 (cs) 2003-04-16
BR0107815A (pt) 2002-10-29
HK1050529A1 (en) 2003-06-27
CN1404472A (zh) 2003-03-19
US20080108591A1 (en) 2008-05-08
SI1250328T2 (sl) 2010-09-30
SK9762002A3 (en) 2003-05-02
US20050165022A1 (en) 2005-07-28
IS6467A (is) 2002-07-11
US7034021B2 (en) 2006-04-25
DE60121294T2 (de) 2007-08-30
YU55602A (sh) 2005-03-15
KR100722438B1 (ko) 2007-05-29
AU3560301A (en) 2001-08-07
ZA200205314B (en) 2005-07-27
MA25650A1 (fr) 2002-12-31
DE60121294D1 (de) 2006-08-17
IL150530A0 (en) 2003-02-12
US7767676B2 (en) 2010-08-03
AP2002002578A0 (en) 2002-09-30
EP1250328B2 (de) 2010-04-21
AR027293A1 (es) 2003-03-19
MXPA02007232A (es) 2003-10-15
US20080108619A1 (en) 2008-05-08
PT1250328E (pt) 2006-10-31
TNSN01012A1 (fr) 2005-11-10
EE200200414A (et) 2003-10-15
US7452883B2 (en) 2008-11-18
CA2397636A1 (fr) 2001-08-02
FR2804113A1 (fr) 2001-07-27
CN1195743C (zh) 2005-04-06
CY1105344T1 (el) 2010-03-03
SK287647B6 (sk) 2011-05-06
DK1250328T4 (da) 2010-06-28
EA005378B1 (ru) 2005-02-24
KR20020075395A (ko) 2002-10-04
EA200200790A1 (ru) 2003-02-27
US20030109530A1 (en) 2003-06-12
DE60121294T3 (de) 2010-09-23
ES2267715T5 (es) 2010-06-10
BRPI0107815B8 (pt) 2021-05-25
BG106933A (en) 2003-07-31
JP2003520858A (ja) 2003-07-08
BRPI0107815B1 (pt) 2017-08-29
HUP0204087A3 (en) 2006-01-30
ES2267715T3 (es) 2007-03-16
PL205345B1 (pl) 2010-04-30
DK1250328T3 (da) 2006-10-30

Similar Documents

Publication Publication Date Title
DE60121294D1 (de) Dihydro-1,3,5-triazin-diamin-derivate und ihre therapeutische verwendung
ATE232865T1 (de) 1,4-diazabicyclo(3.2.2)nonan-4-carboxylat und carboxamidderivate, ihre herstellung und therapeutische verwendung
DE60036803D1 (de) Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
DE60127997D1 (de) 1,5-benzothiazepine und ihre verwendung als antihyperlipidämika
DE60139477D1 (de) 2-cyanopyrrolidin-derivate und ihre verwendung als arzneimittel
ATE424202T1 (de) Substituierte 2-thio-3,5-dicyano-4-phenyl-6- aminopyridine und ihre verwendung
DE60107859D1 (de) Benzimidazolderivate, ihre herstellung und therapeutische verwendung
ATE231869T1 (de) Pyridopyranoazepinderivate, ihre herstellung und therapeutische verwendung
DE50207849D1 (de) Substituierte 2-oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre verwendung
ATE448238T1 (de) 3-beta-d-ribofuranosylthiazolo(4,5- delta)pyridimin-nucleoside und ihre verwendung
DE60039539D1 (de) 4-aminopiperidin-derivate und ihre verwendung als arzneimittel
DE60103394D1 (de) 4-(2-phenylthiazol-5-yl)1,4-diazabicyclo[3.2.2]nonanederivate, ihre herstellung und therapeutische verwendung
DE60103054D1 (de) Phenyloxazol-1,4-diazabicyclo[3.2.2]nonanderivate, ihre herstellung und ihre therapeutische verwendung
ATE312828T1 (de) Acylaminothiazolderivate, deren herstellung und deren therapeutische verwendung
ATE247109T1 (de) Substituierte benzoylisoxazole und ihre verwendung als herbizide
DE60321372D1 (de) 3-phenylpyridoindolderivate, ihre herstellung und verwendung
ATE337321T1 (de) Cabapenemderivate, ihre anwendung und ihre zwischenprodukte
DE50008549D1 (de) Triazolotriazinone und ihre verwendung
ATE212346T1 (de) 3-substituierte tetrahydropyridopyrimidinon- derivate, ihre herstellung und verwendung
DE60144456D1 (de) DibenzoÄb,fÜazepin-Derivate und ihre Herstellung
ATE249451T1 (de) Benzofuranderivate, ihre herstellung und verwendung
DE50313185D1 (de) 2-pyrrolidin-2-yl-ä1,3,4ü -oxadiazol-derivate und ihre verwendung als antidepressiva
ATE236905T1 (de) 4-oxo-3,5-dihydro-4h-pyridazino(4,5-b)indol-1- carboxamid-derivate, ihre herstellung und therapeutische verwendung
ATE347544T1 (de) Substituierte phenylcyclohexancarbonsäureamide und ihre verwendung
ATE293621T1 (de) Imidazolin-derivate, ihre herstellung und ihre verwendung als entzündungshemmende mittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1250328

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1250328

Country of ref document: EP